title: [Utility of daily oral administration of etoposide in 25 cases of refractory hematological malignancies].
abstract: We estimated the utility of daily oral administration of etoposide (ETOP) in 25 cases of refractory hematological malignancies who had been admitted to our hospital between February, 1988 and October, 1995. Patients were 9 cases of malignant lymphoma, 7 cases of adult T cell leukemia (ATL), 7 cases of acute leukemia, 1 case of primary macroglobulinemia, and 1 case of chronic lymphocytic leukemia (CLL). Eight cases were elderly patients over 65 years old, 7 cases were refractory to previous chemotherapies, and 13 cases were relapsed cases. ETOP was administered at 25 or 50 mg per day for at least more than 3 consecutive weeks, if the peripheral white blood cell count exceeded 1,000/microliter. Complete and partial responses were obtained in 64% of all cases, especially in 81% of malignant lymphoma and ATL. Probability of survival for 3 years of malignant lymphoma and ATL was 36.7%. As mild toxicities, 2 cases (8%) had nausea and vomiting, 2 cases (8%) had diarrhea, and 3 cases (12%) had stomatitis. Grade 3 leukocytopenia was observed in 16% of cases. Twelve out of 16 evaluable patients recovered in performance status (PS) after this therapy. Daily oral administration of ETOP might be an effective therapy for refractory hematological malignancies, especially for malignant lymphoma.
authors.affiliation: Dept. of Internal Medicine, Japanese Red Cross Asahikawa Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Kuga
authors.forename: K
authors.initials: K
authors.lastname: Kohda
authors.forename: S
authors.initials: S
authors.lastname: Matsumoto
authors.forename: O
authors.initials: O
authors.lastname: Nakazawa
authors.forename: A
authors.initials: A
authors.lastname: Ezoe
authors.forename: A
authors.initials: A
authors.lastname: Nobuoka
authors.forename: C
authors.initials: C
authors.lastname: Mochizuki
authors.forename: Y
authors.initials: Y
authors.lastname: Niitsu
authors.forename: N
authors.initials: N
authors.lastname: Watanabe
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D015458:Leukemia, T-Cell / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D013280:Stomatitis / Q000139:chemically induced; D016019:Survival Analysis; D014839:Vomiting / Q000139:chemically induced; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy
chemical_list: D005047:Etoposide